אנדרנוקורטיקל קרצינומה

להלן דו"ח של טיפולים ביולוגיים ב : • Bevacizumab plus capecitabine: The rationale for the combination therapy was inhibition of VEGF signaling and promotion of cytotoxic response, but no responses were seen among the 10 study participants with advanced disease. • OSI-906: In a phase III study of the small-molecule tyrosine kinase IGF-1R inhibitor, five of 16 patients with advanced ACC showed partial tumor responses or stable disease. • Erlotinib plus gemcitabine: The combination was used to inhibit EGFR signaling and elicit cytotoxic response. Ten patients with advanced disease were treated, but only one experienced a minor response, leading the researchers to conclude that the treatment has "limited to no activity" in advanced ACC. • Figitumumab: Eight of 14 patients with refractory ACC treated with the anti-IGF-1R monoclonal antibody had stable disease, leading the researchers to conclude that the drug warrants further consideration in the treatment of ACC. • Gefitinib: The EGFR signal-inhibiting drug showed no activity in (no responses) in the phase II trial including 19 patients with unresectable ACC. • Thalidomide: The anti-angiogenic compound that inhibits the activity of bFGF-2 elicited a partial response when used to treat a single patient. • Imatinib: No responses were seen in four ACC patients with either c-KIT or PDGF-positive tumors. ACC טיפולים משלימים: היפרתרמיה, גלוונו ד"ר יוסף ברנר